Revenue nearly doubled at digital pharmacy TelyRx, but it lost $2.7 million from operations.
TelyRx reported Q3 2026 revenue of $23.1M, up from $12.3M in Q3 2025, but net loss from operations widened to $2.7M from $0.9M. Adjusted EBITDA loss narrowed to $1.3M from $0.4M. The company launched a new brand and website, expanded its formulary, and plans to triple capacity in Clearwater, Florida.
How this was made
The 30-second read
Why it matters
The earnings release provides fresh data for traders evaluating small‑cap digital health stocks, highlighting both top‑line growth and ongoing loss challenges.
Market read
First‑report earnings for a micro‑cap health‑tech firm; modest trading relevance but new data for valuation models.
What to watch
The company’s cash balance surged, providing runway; however, the need for additional financing remains uncertain.
Background
TelyRx Holdings Inc. released its Q3 2026 financial results, showing revenue growth to $23.1 M and a net loss from operations of $2.7 M.
Market effects
Digital pharmacy and tele‑health providers may see heightened investor interest as revenue growth outpaces loss reduction.
Primarily affects U.S. small‑cap investors; limited broader market effect.
Limited to niche health‑tech niche; no major global market shift.
Counterpoint
Despite revenue doubling, widening operating loss could signal cash‑burn concerns that outweigh growth headlines.
Key entities
- CompanyTelyRx Holdings Inc.
Digital pharmacy platform reporting Q3 2026 results.




